S295 The Impact of Fecal Diversion on Immune Checkpoint Inhibitor Adverse GI Toxicities

Saltenat Moghaddam Adames,Sidra Naz,Jianliang Dai,Yinghong Wang,Anusha Thomas
DOI: https://doi.org/10.14309/01.ajg.0001030548.48060.a9
2024-10-26
The American Journal of Gastroenterology
Abstract:Immune check point inhibitors (ICIs) are highly efficacious cancer therapies used in a wide variety of malignancies. ICIs work by blocking the immune system suppression cascade to create an unmitigated immune response against cancer. However, this unmitigated response can predispose patients to immune mediated colitis (IMC). IMC is graded via the Common Terminology Criteria for Adverse Events (CTCAE) classification system and can vary from a mild diarrhea to an aggressive colitis. It is known that diversion of fecal stream can alter the gut microbiota and thereby impact the severity of gut inflammation. In this study, we aim to study cancer patients on ICIs with diversion of fecal stream and its outcome on IMC.
gastroenterology & hepatology
What problem does this paper attempt to address?